BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

929 related articles for article (PubMed ID: 18701494)

  • 21. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
    Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB.
    Ma Y; Wang J; Liu L; Zhu H; Chen X; Pan S; Sun X; Jiang H
    Cancer Lett; 2011 Feb; 301(1):75-84. PubMed ID: 21078540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
    Armeanu S; Krusch M; Baltz KM; Weiss TS; Smirnow I; Steinle A; Lauer UM; Bitzer M; Salih HR
    Clin Cancer Res; 2008 Jun; 14(11):3520-8. PubMed ID: 18519785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
    Chen J; Ouyang ZG; Zhang SH; Zhen YS
    Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
    Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY
    Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway.
    Chen C; Chang YC; Liu CL; Liu TP; Chang KJ; Guo IC
    Endocr Relat Cancer; 2007 Jun; 14(2):513-29. PubMed ID: 17639064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis.
    Zhao J; Dong L; Lu B; Wu G; Xu D; Chen J; Li K; Tong X; Dai J; Yao S; Wu M; Guo Y
    Gastroenterology; 2008 Sep; 135(3):956-68. PubMed ID: 18555021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins.
    Nishikawa T; Nakajima T; Moriguchi M; Jo M; Sekoguchi S; Ishii M; Takashima H; Katagishi T; Kimura H; Minami M; Itoh Y; Kagawa K; Okanoue T
    J Hepatol; 2006 Jun; 44(6):1074-82. PubMed ID: 16481065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
    Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
    Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
    Michaelis M; Fichtner I; Behrens D; Haider W; Rothweiler F; Mack A; Cinatl J; Doerr HW; Cinatl J
    Int J Oncol; 2006 Feb; 28(2):439-46. PubMed ID: 16391799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
    Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    Shringarpure R; Catley L; Bhole D; Burger R; Podar K; Tai YT; Kessler B; Galardy P; Ploegh H; Tassone P; Hideshima T; Mitsiades C; Munshi NC; Chauhan D; Anderson KC
    Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
    Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
    BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Chu S; Alexiadis M; Fuller PJ
    Reprod Sci; 2009 Apr; 16(4):397-407. PubMed ID: 19087975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.